Saniona AB
Saniona postpones 2020 year-end financial report due to restatement and re-audit of prior period financial statements in line with U.S. PCAOB audit standards
PRESS RELEASE
February 22, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that, as part of its previously announced evaluation of a potential listing of its shares on the U.S. Nasdaq exchange, Saniona is conducting a company-initiated restatement of prior period financial statements and a subsequent audit of these financial statements under U.S. Public Company Accounting Oversight Board (PCAOB) audit standards. This will result in the postponement of its 2020 year-end report. The 2020 year-end report will be issued on 17 March 2021.
Saniona deems the restatements, which relate to accounting adjustments, to not be material from a business perspective because they will not impact the Company’s cash position, forecast, operating plan or the conduct of its clinical trials.
In preparation for a potential U.S. listing, Saniona is auditing its financial statements under standards adopted by the PCAOB and identified the need to make certain accounting adjustments to its previously issued financial statements for the full year 2019, and certain quarterly periods in 2019 and 2020. The adjustments relate to the accounting for investments in third-party entities, the accounting for financial instruments, and the recognition of certain revenue and expenses, among other items. Saniona has engaged independent auditors to perform an audit of the restated financial statements in accordance with PCAOB standards. The restated financial statements will continue to be presented in accordance with International Financial Reporting Standards (IFRS) standards.
For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com
The information was submitted for publication, through the agency of the contact person set out above, at 23:59 CET on 22 February 2021.
About Saniona
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
Attachment
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Vestjysk Bank A/S4.3.2021 13:16:51 CET | Press release
Vestjysk Bank A/S has issued DKK 140 million Senior Non-Preferred
Vestjysk Bank A/S4.3.2021 13:16:41 CET | Pressemeddelelse
Vestjysk Bank A/S udsteder DKK 140 millioner Senior Non-Preferred
Bombardier Inc.4.3.2021 13:02:07 CET | Press release
Bombardier Provides 2025 Financial Targets and Highlights Progress on Key Earnings Growth and Cash Generation Drivers at Virtual Investor Day
Hatch Ltd4.3.2021 13:01:56 CET | Press release
Hatch celebrates 65th anniversary with release of new campaign, "Positive change: leadership for a better world"
Municipality Finance Plc4.3.2021 13:01:46 CET | Press release
Municipality Finance’s Annual Report for 2020 published
Aspo Oyj4.3.2021 13:01:36 CET | Press release
Aspo Group’s Financial Statements and Sustainability Report 2020 published
Investeringsforeningen PFA Invest4.3.2021 12:11:42 CET | Pressemeddelelse
Anmodning om suspension af samtlige afdelinger i Investeringsforeningen PFA Invest
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom